Anti-Angiogenic Agents Combined with Immunotherapy for AdvancedNon-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Anti-angiogenesis combined with immunotherapy demonstrated satisfactory antitumor activity and an acceptable toxicity profile in patients with advanced NSCLC. The pooled results of our meta-analysis provided further evidence supporting the favorable efficacy and safety of this therapeutic strategy.